Idarubicine

Lymphoma

Shanghai General Hospital, Shanghai Jiao Tong University School of MedicinePhase 3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 58/ 100
Competitive Position: 65/ 100

Competitive context

288 Active assets in the Lymphoma cohort.

Asset / Sponsor	Phase	Rating
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE The Lymphoma Academic Research Organisation	Phase 4	BBB
VINBLASTINE Intensity Therapeutics, Inc.	Phase 4	BBB
VINCRISTINE SULFATE Inhye Ahn	Phase 3	BB
BLEOMYCIN Shandong Provincial Hospital	Phase 4	BB
ETOPOSIDE Memorial Sloan Kettering Cancer Center	Phase 4	BB

View all 50 →

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant

A

Indicative ·

81 / 100

Acute Promyelocytic LeukemiaDormant

BBB

Indicative ·

78 / 100

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant

BBB

Indicative ·

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.